.
MergerLinks Header Logo

Announced

Sonnet BioTherapeutics to acquire Relief Therapeutics.

Financials

Edit Data
Transaction Value-
Consideration Type-
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Switzerland

treatment development

Private

Friendly

Biotechnology

Pending

Single Bidder

Synopsis

Edit

Sonnet BioTherapeutics, a privately held, oncology-focused biotechnology company, agreed to acquire Relief Therapeutics, a drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. Under the terms of the deal, Relief Therapeutics will receive 7.1m of Sonnet’s common shares. “The acquisition of Relief’s subsidiary by Sonnet well positions the Atexakin development program by propelling it forward towards the market with the ultimate goal of hopefully positively transforming the lives of affected patients” commented Raghuram Selvaraju, PhD, MBA, Chairman of Relief. “We are excited about the opportunity to work with the Sonnet team, which brings extensive drug development expertise and will add supplementary value to that brought by the previous developments of the Asset.”

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US